Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹69.45
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.32B
Enterprise Value₹442.94M
Total Cash (Recent Filing)₹388.49M
Total Debt (Recent Filing)₹565.23M
Price to Earnings (P/E)112.0
Beta0.92
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.60
Price to Sales (P/S)1.28
P/FCF Ratio-6.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectorySustained top-line growth between 2024 and 2025 indicates expanding product uptake and distribution reach. Over 2-6 months this supports scale advantages, enables reinvestment in marketing or capacity, and provides a buffer against cyclical downturns if execution and margins hold.
Solid Gross And EBIT MarginsConsistently healthy gross and EBIT margins imply durable operational control and pricing power in core formulations sales. Margin strength supports cash generation potential, resilience to input cost shocks, and the ability to fund growth or absorb temporary revenue volatility over a multi-month horizon.
Healthy Equity Base / Low Debt-to-EquityA strong equity ratio and historically low debt-to-equity provide financial flexibility and lower default risk. This foundational balance-sheet strength supports capital allocation choices (capex, working capital or strategic investments) and reduces reliance on costly external financing over the medium term.
Bears Say
Negative Free Cash FlowA swing to negative free cash flow driven by weaker operating cash flow and higher capex raises sustainability concerns. Persisting cash deficits can force external financing, constrain investment or working capital, and increase refinancing or dilution risk within a 2-6 month planning horizon.
Volatile Net IncomeMarked volatility in net income reduces earnings predictability and complicates strategic planning. Persistent swings suggest exposure to one-off items, variable costs, or pricing pressure, which can undermine stakeholder confidence and make capital allocation less efficient over coming quarters.
Substantial Increase In Total Debt (2025)A material rise in total debt in 2025 elevates leverage and interest burden precisely when operating cashflow turned negative. Higher indebtedness reduces financial flexibility, raises refinancing risk, and increases vulnerability to margin or revenue shocks over the medium term.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹69.45 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.32B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 54 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Currently, no data Available
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Gkb Ophthalmics Limited
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―